The burden of psoriasis and barriers to satisfactory care: Results from a canadian patient survey

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue 6, 2009, Pages 283-293

  Mahler, Ronald ^a,b,c,d   Jackson, Christine ^a,b,c   Ijacu, Horia ^a,b,c  

^a LAKEHEAD UNIVERSITY   (Canada)

^b Canadian Skin Patient Alliance   (Canada)

^c EMD Serono Canada Inc   (Canada)

^d NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANADA; CHI SQUARE DISTRIBUTION; COMORBIDITY; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; INCOME; INTERNET; MALE; MIDDLE AGED; PATIENT SATISFACTION; PREVALENCE; PSORIASIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICS; UNEMPLOYMENT;

ADOLESCENT; ADULT; CANADA; CHI-SQUARE DISTRIBUTION; COMORBIDITY; FEMALE; HUMANS; INCOME; INTERNET; MALE; MIDDLE AGED; PATIENT SATISFACTION; PREVALENCE; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; UNEMPLOYMENT;

EID: 77649228915     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.08083     Document Type: Review

References (33)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535-46.
2. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36.
3. Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 spring US National Psoriasis Foundation survey. Am J Clin Dermatol 2008;9:111-7.
4. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8.
5. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008;19:5-21.
6. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:103-42.
7. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004;45:155-9; quiz 60-1.
8. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37.
9. Collins KA, Westra HA, Dozois DJ, Burns DD. Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin Psychol Rev 2004;24:583-616.
10. Stein MB. Public health perspectives on generalized anxiety disorder. J Clin Psychiatry 2004;65 Suppl 13:3-7.
11. Pearce DJ, Singh S, Balkrishnan R, et al. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006;17:24-8.
12. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007;57:963-71.
13. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003;49:897-9.
14. Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008;58:964-9.
15. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007;156:945-50.
16. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
17. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57:957-62.
18. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005;141:19-26.
19. Statistics Canada. A report on mental illness in Canada. Chapter 4: Anxiety disorders. Available at: http://www.phac-aspc.gc.ca/publicat/miic-mmac/ chap-4-e.html (accessed August 2008).
20. Statistics Canada. A report on mental illness in Canada. Chapter 2: Mood disorders. Available at: http://www.phac-aspc.gc.ca/publicat/miic-mmac/chap-2-e. html (accessed August 2008).
21. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92.
22. Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9:131-5.
23. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861-7.
24. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-7.
25. Scharloo M, Kaptein AA, Weinman J, et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000;142:899-907.
26. Statistics Canada. Persons with diabetes, by age and sex. Available at: http://www40.statcan.ca/l01/cst01/health53a.htm?sdi5diabetes (accessed August 2008).
27. Statistics Canada. Persons with high blood pressure, by age and sex. Available at: http://www40.statcan.ca/l01/cst01/health03.htm (accessed August 2008).
28. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9.
29. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35.
30. Kulkarni AS, Balkrishnan R, Richmond D, et al. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol 2005;52:27-31.
31. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg 2004;8:321-37.
32. Pariser DM, Bagel J, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007;143:239-42.
33. Allin S, Hurley J. Inequity in publicly funded physician care. What is the role of private prescription drug insurance? Health Econ 2008. DOI: 10.1002/hec.1428.